The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer.

ABSTRACT:

Objective

While PD-L1 expression serves as a predictive biomarker for programmed cell death 1 and its ligand (PD-1/PD-L1) inhibitor efficacy in patients with non-small cell lung cancer (NSCLC), its association with treatment-related adverse events (TRAEs) has yet to be fully elucidated. This study systematically evaluated the correlation between PD-L1 expression status and TRAEs in patients with NSCLC.

Methods

We systematically searched the Cochrane Library, Embase, and PubMed databases from inception to June 30, 2024, to identify prospective clinical trials examining PD-1/PD-L1 inhibitors among NSCLC patients that reported treatment-related toxicity data stratified by PD-L1 expression.

Results

Twenty-six prospective trials (N = 5,453) were analyzed. At the 1%, 25%, a

SUBMITTER: Zhu Q 

PROVIDER: S-EPMC12039059 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature